Phylon Pharma Serv

• 2018 Selective inhibition of receptor activator of NF-κB ligand (RANKL) in hematopoietic cells improves outcome after experimental myocardial infarction.

Download
 RDF/XML-Format
 JSON-LD-Format
 Turtle-Format
 N3-Format